United Therapeutics (UTHR) Competitors $368.60 -12.18 (-3.20%) Closing price 03:59 PM EasternExtended Trading$367.43 -1.17 (-0.32%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends UTHR vs. ALNY, BIIB, INCY, BMRN, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Alnylam Pharmaceuticals Biogen Incyte BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals United Therapeutics (NASDAQ:UTHR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Is UTHR or ALNY more profitable? United Therapeutics has a net margin of 40.31% compared to Alnylam Pharmaceuticals' net margin of -12.37%. United Therapeutics' return on equity of 19.22% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.31% 19.22% 16.15% Alnylam Pharmaceuticals -12.37%N/A -6.83% Which has preferable valuation and earnings, UTHR or ALNY? United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$2.33B7.30$984.80M$22.7716.72Alnylam Pharmaceuticals$2.25B14.42-$278.16M-$2.17-115.44 Does the MarketBeat Community prefer UTHR or ALNY? Alnylam Pharmaceuticals received 548 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 76.20% of users gave Alnylam Pharmaceuticals an outperform vote while only 62.50% of users gave United Therapeutics an outperform vote. CompanyUnderperformOutperformUnited TherapeuticsOutperform Votes59562.50% Underperform Votes35737.50% Alnylam PharmaceuticalsOutperform Votes114376.20% Underperform Votes35723.80% Does the media refer more to UTHR or ALNY? In the previous week, Alnylam Pharmaceuticals had 38 more articles in the media than United Therapeutics. MarketBeat recorded 53 mentions for Alnylam Pharmaceuticals and 15 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.59 beat Alnylam Pharmaceuticals' score of 0.40 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 20 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, UTHR or ALNY? United Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Do institutionals and insiders believe in UTHR or ALNY? 94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 11.9% of United Therapeutics shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate UTHR or ALNY? United Therapeutics presently has a consensus price target of $382.08, indicating a potential upside of 0.34%. Alnylam Pharmaceuticals has a consensus price target of $299.48, indicating a potential upside of 19.55%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72 SummaryUnited Therapeutics beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.64B$6.96B$5.80B$9.23BDividend YieldN/A2.90%5.23%3.99%P/E Ratio16.724.0321.2517.07Price / Sales7.30324.54467.5579.17Price / Cash16.8872.7844.6938.04Price / Book2.996.507.695.18Net Income$984.80M$138.54M$3.19B$246.13M7 Day Performance2.79%-0.05%0.34%0.14%1 Month Performance6.09%1.58%3.78%1.10%1 Year Performance77.80%-1.59%19.92%16.36% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.3231 of 5 stars$368.60-3.2%$382.08+3.7%+77.3%$16.46B$2.33B16.191,168Insider TradeALNYAlnylam Pharmaceuticals4.5383 of 5 stars$256.45-3.2%$299.43+16.8%+70.4%$33.08B$1.83B-97.882,100Earnings ReportAnalyst ForecastInsider TradeShort Interest ↓BIIBBiogen4.8357 of 5 stars$137.33-0.8%$211.96+54.3%-37.7%$20.01B$9.84B12.417,570Analyst ForecastAnalyst RevisionINCYIncyte4.5735 of 5 stars$70.42+0.6%$75.59+7.3%+21.0%$13.57B$3.70B503.042,524BMRNBioMarin Pharmaceutical4.9345 of 5 stars$64.85+0.7%$94.20+45.3%-26.1%$12.36B$2.42B38.833,401Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpNBIXNeurocrine Biosciences4.9881 of 5 stars$115.02-1.6%$166.90+45.1%-13.6%$11.65B$2.36B34.961,400Analyst DowngradeAnalyst RevisionEXELExelixis4.6743 of 5 stars$35.00+1.5%$37.24+6.4%+71.2%$10.00B$1.83B22.441,310Analyst UpgradeInsider TradeShort Interest ↓EXASExact Sciences4.7483 of 5 stars$49.31-2.5%$72.76+47.6%-17.2%$9.13B$2.50B-42.146,600Earnings ReportAnalyst ForecastNews CoverageGap DownRGENRepligen3.9108 of 5 stars$146.92+0.5%$182.91+24.5%-27.7%$8.23B$638.76M-397.071,783Earnings ReportNews CoveragePositive NewsGap UpHALOHalozyme Therapeutics4.7758 of 5 stars$58.29-0.5%$60.89+4.5%+60.0%$7.42B$829.25M19.30390Earnings ReportAnalyst ForecastNews CoverageMDGLMadrigal Pharmaceuticals3.5123 of 5 stars$337.20-4.1%$351.67+4.3%+47.4%$7.35BN/A-13.4490 Related Companies and Tools Related Companies ALNY Alternatives BIIB Alternatives INCY Alternatives BMRN Alternatives NBIX Alternatives EXEL Alternatives EXAS Alternatives RGEN Alternatives HALO Alternatives MDGL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UTHR) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
